评估一剂或两剂人乳头瘤病毒疫苗的双盲随机非劣效性临床试验的原理与设计:包含估算疫苗效力的流行病学调查(哥斯达黎加ESCUDDO试验)
该试验在哥斯达黎加12至16岁女孩中随机分配一剂或两剂二价及九价HPV疫苗,主要终点为预防持续6个月以上的新发HPV16/18感染的非劣效性。同时通过未接种女性调查估算疫苗效力,计划随访至5年。
要点
- 世界卫生组织推荐青春期女孩接种两剂HPV疫苗,但高疾病负担地区接种比例低。
- 哥斯达黎加HPV疫苗试验提示一剂二价疫苗可提供超过十年的持久保护。
- ESCUDDO试验随机分配20,330名女孩至一剂或两剂二价及九价疫苗组,随访至5年。
核心结论
- ESCUDDO试验旨在正式比较一剂与两剂二价及九价HPV疫苗在预防持续6个月以上新发HPV16/18感染中的非劣效性,并通过流行病学调查估算疫苗效力。
研究设计与样本
- 双盲随机非劣效性临床试验,按1:1:1:1随机分配至一剂和两剂二价及九价疫苗组,纳入20,330名12至16岁哥斯达黎加女孩,每6个月随访一次,最长5年;另纳入未接种女性调查(起始N=4452,计划第4.5年N=3000),调查参与者间隔6个月参加两次访视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HPV vaccination of adolescent girls is the most effective measure to prevent cervical cancer. The World Health Organization recommends that adolescent girls receive two doses of vaccine but only a small proportion of girls from regions with the highest disease burden are vaccinated because of cost and logistical considerations. Our Costa Rica HPV Vaccine trial suggested that one dose of the bivalent HPV vaccine provides robust and lasting protection against persistent HPV infections for over a decade. Data from a post-licensure trial of the quadrivalent vaccine in India also suggested that a single dose may be effective in reducing cervical cancer risk. To formally compare one versus two doses of the bivalent and nonavalent HPV vaccines, we implemented a large, randomized, double-blind trial to investigate the non-inferiority of one compared to two vaccine doses in the prevention of new HPV16/18 infections that persist 6 or more months. Bivalent and nonavalent vaccines will be evaluated separately. The trial enrolled and randomized (1:1:1:1 to 1- and 2-dose arms of the bivalent and nonavalent vaccines) 20,330 girls 12 to 16 years old residing in Costa Rica. Trial participants are followed every 6 months for up to 5 years. We also aim to estimate vaccine efficacy by comparing the rates of 6 month persistent infection in unvaccinated women with the rates in the follow-up visits of trial participants. We included one survey of unvaccinated women at the start of the study (N = 4452) and will include another survey concomitant with follow up visits of trial participants at year 4.5 (planned N = 3000). Survey participants attend two visits 6 months appart. Herein, we present the rationale, design, and enrolled study population of the ESCUDDO trial. ClinicalTrials.gov Identifier: NCT03180034.
引用
- Porras C, Sampson JN, Herrero R, et al. Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. Vaccine. 2021. PMID: 34857420. doi:10.1016/j.vaccine.2021.11.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。